Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Single doublecortin gene therapy significantly reduces glioma tumor volume.

Authors: Santra, Manoranjan  Zheng, Xuguang  Roberts, Cindi  Santra, Sutapa  Lu, Mei  Panda, Swayamprava  Jiang, Feng  Chopp, Michael 
Citation: Santra M, etal., J Neurosci Res. 2010 Feb 1;88(2):304-14. doi: 10.1002/jnr.22207.
Pubmed: (View Article at PubMed) PMID:19681167
DOI: Full-text: DOI:10.1002/jnr.22207

We employed lentivirus-based doublecortin (DCX), as a glioma suppressor gene therapy in an intracranial glioma tumor xenograft model in nude rats. Single DCX-expressing lentivirus was directly administered into the tumor on day 8 after U87 tumor cell implantation. DCX treatment significantly reduced U87 glioma tumor volume (approximately 60%) on day 14 after DCX lentivirus injection and significantly improved median survival of tumor-bearing nude rats. DCX synthesis induced neuronal markers MAP2, TUJ1, and PSA-NCAM and the glial marker glial fibrillary acidic protein (GFAP) in the implanted U87 glioma tumors. DCX synthesis induced GFAP that colocalized with tubulin in the mitotic stage, inhibited cleavage furrow during cytokinesis, and blocked mitosis in glioma cells. DCX lentivirus infection did not induce apoptosis but significantly inhibited expression of the proliferation marker Ki-67 and the blood vessel marker von-Willebrand factor (vWF). U87 and other glioma cells except for brain tumor stem cells (BTSCs) do not express neuronal markers or both neuronal and glial markers. DCX-synthesizing glioma cells express a phenotype of antiangiogenic BTSC-like cells with terminal differentiation that causes remission of glioma cells by blocking mitosis via a novel DCX/GFAP pathway. Direct local delivery of lentivirus-based DCX gene therapy is a potential differentiation-based therapeutic approach for the treatment of glioma.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 12904754
Created: 2017-05-22
Species: All species
Last Modified: 2017-05-22
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.